Sancho Jesús, Martínez Daniel, Bures Enric, Díaz José Luis, Ponz Alejandro, Servera Emilio
Respiratory Care Unit, Respiratory Medicine Dept, Hospital Clínico Universitario, Valencia, Spain.
Research Group for Respiratory Problems in Neuromuscular Disease, Institute of Health Research INCLIVA, Valencia, Spain.
ERJ Open Res. 2018 Apr 16;4(2). doi: 10.1183/23120541.00159-2017. eCollection 2018 Apr.
There is general agreement that noninvasive ventilation (NIV) prolongs survival in amyotrophic lateral sclerosis (ALS) and that the main cause of NIV failure is the severity of bulbar dysfunction. However, there is no evidence that bulbar impairment is a contraindication for NIV. The aim of this study was to determine the effect of bulbar impairment on survival in ALS patients with NIV. ALS patients for whom NIV was indicated were included. Those patients who refused NIV were taken as the control group. 120 patients who underwent NIV and 20 who refused NIV were included. The NIV group presented longer survival (median 18.50 months, 95% CI 12.62-24.38 months) than the no-NIV group (3.00 months, 95% CI 0.82-5.18 months) (p<0.001) and also in those patients with severe bulbar dysfunction (13.00 months (95% CI 9.49-16.50 months) 3.00 months (95% CI 0.85-5.15 months), p<0.001). Prognostic factors for ALS using NIV, adjusted for NIV failure, were severity of bulbar dysfunction (hazard ratio (HR) 0.5, 95% CI 0.92-0.97; p=0.001) and time spent with oxygen saturation measured by pulse oximetry <90% (%sleep <90) using NIV (HR 1.12, 95% CI 1.01-1.24; p=0.02). Severe bulbar impairment in ALS does not always prevent NIV from being used, but the severity of bulbar dysfunction at NIV initiation and %sleep <90 while using NIV appear to be the main prognostic factors of NIV failure in ALS.
普遍认为,无创通气(NIV)可延长肌萎缩侧索硬化症(ALS)患者的生存期,且无创通气失败的主要原因是延髓功能障碍的严重程度。然而,没有证据表明延髓损害是无创通气的禁忌症。本研究的目的是确定延髓损害对接受无创通气的ALS患者生存期的影响。纳入了有指征接受无创通气的ALS患者。将那些拒绝无创通气的患者作为对照组。纳入了120例接受无创通气的患者和20例拒绝无创通气的患者。无创通气组的生存期(中位数18.50个月,95%置信区间12.62 - 24.38个月)长于未接受无创通气组(3.00个月,95%置信区间0.82 - 5.18个月)(p<0.001),在那些有严重延髓功能障碍的患者中也是如此(13.00个月(95%置信区间9.49 - 16.50个月)对3.00个月(95%置信区间0.85 - 5.15个月),p<0.001)。在对无创通气失败进行校正后,使用无创通气的ALS患者的预后因素为延髓功能障碍的严重程度(风险比(HR)0.5,95%置信区间0.92 - 0.97;p = 0.001)以及使用无创通气时经脉搏血氧饱和度测定的氧饱和度<90%的时间(%睡眠<90)(HR 1.12,95%置信区间1.01 - 1.24;p = 0.02)。ALS患者的严重延髓损害并不总是妨碍使用无创通气,但开始无创通气时延髓功能障碍的严重程度以及使用无创通气时%睡眠<90似乎是ALS患者无创通气失败的主要预后因素。